The collaboration will strengthen the distribution and marketing of semaglutide for weight loss

Novo Nordisk India and Emcure Pharma announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

Poviztra is a second brand of Wegovy. The partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, semaglutide injection 2.4 mg, in India.

Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk said, “Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership
brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing and distribution capabilities to improve access to obesity treatment for people living with overweight or obesity in India.”

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma said, “We are thrilled to partner with Novo Nordisk India to bring Poviztra® to India and are proud to be the first Indian pharmaceutical company to bring the world’s most widely used and trusted GLP-1-based weight loss molecule to the Indian market. We believe in the potential of semaglutide. With our strong understanding of the country’s diverse geographical landscape and established marketing capabilities, we are confident about making this molecule available to patients who need it the most.”